Registrational Phase III trial in Type 1 Diabetes with Diamyd® expands to the US
The first clinical site in the United States is pending imminent initiation in the precision medicine Phase III trial DIAGNODE-3, which is ongoing in eight European countries. DIAGNODE-3 is designed to confirm the efficacy and safety of the antigen-specific immunotherapy Diamyd[®] in patients aged 12 to 29 years recently diagnosed with type 1 diabetes and carrying the genetic HLA DR3-DQ2 marker. The goal is to have the trial fully enrolled in the second half of 2024.Final preparations are in place to initiate the first clinical site for DIAGNODE-3 in the United States, and additional sites